Cavotec Group AB

As of June 30, 2026, Cavotec Group AB carries a market capitalization of 1.40B, placing it among publicly traded companies globally. Its enterprise value stands at 1.52B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cavotec Group AB's next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Cavotec Group AB has 106.70M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.77, and the price-to-book ratio stands at 2.74.

As of June 30, 2026, Cavotec Group AB trades at an EV/EBITDA multiple of 33.71 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.84 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.52B versus a market cap of 1.40B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Cavotec Group AB maintains a current ratio of 1.19, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 52.98, indicating elevated leverage, while an interest coverage ratio of 1.76 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Cavotec Group AB posted a negative return on equity (ROE) of -14.10, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.89, reflecting losses generated across the asset base. The company generates approximately 2.51M in revenue per employee across its workforce of 718.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.24 indicates how many times Cavotec Group AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Cavotec Group AB recorded 36.12M in income tax expense. The company reported a pretax loss of -44.12M and -80.24M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Cavotec Group AB's stock has declined approximately 37.27% over the past 52 weeks. The 50-day moving average sits at 11.81, while the 200-day moving average is 12.60.

Over the twelve months ended June 30, 2026, Cavotec Group AB generated 1.80B in revenue and converted that into -80.24M in net income, yielding earnings per share of -0.76. EBITDA reached 44.97M, while operating income came in at -23.61M.

As of June 30, 2026, Cavotec Group AB holds 152.00M in cash and equivalents against 270.31M in total debt, resulting in a net debt position of -21.30M. Total book value stands at 510.25M, with working capital of 168.24M providing operational flexibility.

Cavotec Group AB produced 85.48M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -14.91M in capital expenditures, free cash flow totaled 70.57M - equivalent to 0.67 per share.

Over the twelve months ended June 30, 2026, Cavotec Group AB posted a gross margin of 48.83, reflecting its pricing power and cost economics. The operating margin of -1.31 and net profit margin of -4.45 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 5.10, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.62, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Cavotec Group AB shareholders.

As of June 30, 2026, Cavotec Group AB has an Altman Z-Score of 1.49, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.